Theranostics for Triple-Negative Breast Cancer

被引：17

作者：

Choi, Hyeryeon ^{[1
]}

Kim, Kwangsoon ^{[2
]}

机构：

[1] Eulji Univ, Eulji Med Ctr, Dept Surg, Sch Med, Seoul 01830, South Korea

[2] Catholic Univ Korea, Coll Med, Dept Surg, Seoul 06591, South Korea

来源：

DIAGNOSTICS | 2023年 / 13卷 / 02期

关键词：

theranostics; nanomedicine; immunotherapy; breast cancer; PEMBROLIZUMAB PLUS CHEMOTHERAPY; GAMMA-SECRETASE INHIBITORS; POLYMERIC MICELLES; CARBON NANOTUBES; DOUBLE-BLIND; ANTITUMOR-ACTIVITY; QUANTUM DOTS; DRUG; DELIVERY; CELLS;

D O I：

10.3390/diagnostics13020272

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer with poor prognosis. Current endocrine therapy or anti HER-2 therapy is not available for these patients. Chemotherapeutic treatment response varies among patients due to the disease heterogeneity. To overcome these challenges, theranostics for treating TNBC have been widely investigated. Anticancer material conjugated nanoparticles with target-binding ligand and tracer agents enable simultaneous drug delivery and visualization of the lesion with minimal off-target toxicity. In this review, we summarize recently FDA-approved targeted therapies for TNBC, such as poly-ADP-ribose polymerase (PARP) inhibitors, check point inhibitors, and antibody-drug conjugates. Particularly, novel theranostic approaches including lipid-based, polymer-based, and carbon-based nanocarriers are discussed, which can provide basic overview of nano-therapeutic modalities in TNBC diagnosis and treatment.

引用

页数：13

共 101 条

[21] Triple-negative breast cancer: Clinical features and patterns of recurrence [J].

Dent, Rebecca ;

Trudeau, Maureen ;

Pritchard, Kathleen I. ;

Hanna, Wedad M. ;

Kahn, Harriet K. ;

Sawka, Carol A. ;

Lickley, Lavina A. ;

Rawlinson, Ellen ;

Sun, Ping ;

Narod, Steven A. .

CLINICAL CANCER RESEARCH, 2007, 13 (15) :4429-4434

[22] Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): a randomised, double-blind, placebo-controlled, phase 3 trial [J].

Dieras, Veronique ;

Han, Hyo S. ;

Kaufman, Bella ;

Wildiers, Hans ;

Friedlander, Michael ;

Ayoub, Jean-Pierre ;

Puhalla, Shannon L. ;

Bondarenko, Igor ;

Campone, Mario ;

Jakobsen, Erik H. ;

Jalving, Mathilde ;

Oprean, Cristina ;

Palacova, Marketa ;

Park, Yeon Hee ;

Shparyk, Yaroslav ;

Yanez, Eduardo ;

Khandelwal, Nikhil ;

Kundu, Madan G. ;

Dudley, Matthew ;

Ratajczak, Christine K. ;

Maag, David ;

Arun, Banu K. .

LANCET ONCOLOGY, 2020, 21 (10) :1269-1282

[23] Chitosan oligosaccharide decorated liposomes combined with TH302 for photodynamic therapy in triple negative breast cancer [J].

Ding, Yinan ;

Yang, Rui ;

Yu, Weiping ;

Hu, Chunmei ;

Zhang, Zhiyuan ;

Liu, Dongfang ;

An, Yanli ;

Wang, Xihui ;

He, Chen ;

Liu, Peidang ;

Tang, Qiusha ;

Chen, Daozhen .

JOURNAL OF NANOBIOTECHNOLOGY, 2021, 19 (01)

[24] Pathological Response in a Triple-Negative Breast Cancer Cohort Treated with Neoadjuvant Carboplatin and Docetaxel According to Lehmann's Refined Classification [J].

Echavarria, Isabel ;

Lopez-Tarruella, Sara ;

Picornell, Antoni ;

Angel Garcia-Saenz, Jose ;

Jerez, Yolanda ;

Hoadley, Katherine ;

Gomez, Henry L. ;

Moreno, Fernando ;

Del Monte-Millan, Maria ;

Marquez-Rodas, Ivan ;

Alvarez, Enrique ;

Ramos-Medina, Rocio ;

Gayarre, Javier ;

Massarrah, Tatiana ;

Ocana, Inmaculada ;

Cebollero, Maria ;

Fuentes, Hugo ;

Barnadas, Agusti ;

Isabel Ballesteros, Ana ;

Bohn, Uriel ;

Perou, Charles M. ;

Martin, Miguel .

CLINICAL CANCER RESEARCH, 2018, 24 (08) :1845-1852

[25] Long-term Clinical Outcomes and Biomarker Analyses of Atezolizumab Therapy for Patients With Metastatic Triple-Negative Breast Cancer A Phase 1 Study [J].

Emens, Leisha A. ;

Cruz, Cristina ;

Eder, Joseph Paul ;

Braiteh, Fadi ;

Chung, Cathie ;

Tolaney, Sara M. ;

Kuter, Irene ;

Nanda, Rita ;

Cassier, Philippe A. ;

Delord, Jean-Pierre ;

Gordon, Michael S. ;

ElGabry, Ehab ;

Chang, Ching-Wei ;

Sarkar, Indrani ;

Grossman, William ;

O'Hear, Carol ;

Fasso, Marcella ;

Molinero, Luciana ;

Schmid, Peter .

JAMA ONCOLOGY, 2019, 5 (01) :74-82

[26] Talazoparib nanoparticles for overcoming multidrug resistance in triple-negative breast cancer [J].

Eskiler, Gamze Guney ;

Cecener, Gulsah ;

Egeli, Unal ;

Tunca, Berrin .

JOURNAL OF CELLULAR PHYSIOLOGY, 2020, 235 (09) :6230-6245

[27] Talazoparib Loaded Solid Lipid Nanoparticles: Preparation, Characterization and Evaluation of the Therapeutic Efficacy In Vitro [J].

Eskiler, Gamze Guney ;

Cecener, Gulsah ;

Dikmen, Gokhan ;

Egeli, Unal ;

Tunca, Berrin .

CURRENT DRUG DELIVERY, 2019, 16 (06) :511-529

[28] Curcumin-Loaded Solid Lipid Nanoparticles Bypass P-Glycoprotein Mediated Doxorubicin Resistance in Triple Negative Breast Cancer Cells [J].

Fathy Abd-Ellatef, Gamal-Eldein ;

Gazzano, Elena ;

Chirio, Daniela ;

Ragab Hamed, Ahmed ;

Belisario, Dimas Carolina ;

Zuddas, Carlo ;

Peira, Elena ;

Rolando, Barbara ;

Kopecka, Joanna ;

Assem Said Marie, Mohamed ;

Sapino, Simona ;

Ramadan Fahmy, Sohair ;

Gallarate, Marina ;

Zaki Abdel-Hamid, Abdel-Hamid ;

Riganti, Chiara .

PHARMACEUTICS, 2020, 12 (02)

[29] Investigation of the antitumor activity and toxicity of long-circulating and fusogenic liposomes co-encapsulating paclitaxel and doxorubicin in a murine breast cancer animal model [J].

Franco, Marina Santiago ;

Roque, Marjorie Coimbra ;

Branco de Barros, Andre Luis ;

Silva, Juliana de Oliveira ;

Cassali, Geovanni Dantas ;

Oliveira, Monica Cristina .

BIOMEDICINE & PHARMACOTHERAPY, 2019, 109 :1728-1739

[30]

Funkhouser J., 2002, CURRENT DRUG DISCOVE, P17

← 1 2 3 4 5 6 7 8 9 10 →